“Failing to plan is planning to fail” states time management guru Alan Lakein. Nowhere does this axiom ring more true than in the tightly controlled world of Rx launches. Given the time and expense required to bring a prescription drug to market, coupled with its limited exclusive lifespan, we must maximize every moment from market conditioning to loss of exclusivity (LOE).

Pfizer Inc. announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression.

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

The new generation of hep C drugs has completely changed the conversation about launches.

Med Ad News’ first edition of the Pharma Leaders of Innovation special feature showcases two CEOs focusing outside the big pharma box and an agency tech leader.

Bringing its brand name to life, Fingerpaint – a marketing innovation agency as well as founding partner and sponsor of Cannes Lions Health – unveiled the first-ever Virtual Reality (VR) Fingerpaint Studio at the Cannes Lions Health Festival. Fingerpaint also launched the agency’s new Hands-On Brands movement in Cannes.

Virtus Pharmaceuticals Inc. – a specialty niche pharmaceutical company and part of the Linden Capital Partners portfolio – announced it launched Prometrium (Progesterone, USP Capsules), the company’s first branded product.

Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread […]

IMS analysis revealed that lower-cost copies of complex biotechnology drugs could save the United States and Europe’s five top markets as much as €98 billion ($110 billion) by 2020.

Immunocore was recognized as SCRIP Awards 2015’s Biotech of the Year. Immunocore is a world-leading biotech company developing novel T cell receptor (TCR) based biological drugs for the treatment of cancer, viral infections and autoimmune disease.